Heat Biologics (NASDAQ:HTBX) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.09), Bloomberg Earnings reports. Heat Biologics had a negative return on equity of 182.19% and a negative net margin of 543.30%.
Heat Biologics stock traded down $0.21 during midday trading on Wednesday, hitting $1.80. 16,380 shares of the stock were exchanged, compared to its average volume of 1,088,214. Heat Biologics has a 52-week low of $1.09 and a 52-week high of $7.90.
Several research analysts recently weighed in on HTBX shares. Brookline Cap M restated a “buy” rating on shares of Heat Biologics in a report on Wednesday, August 1st. Eurobank EFG started coverage on shares of Heat Biologics in a report on Monday, July 9th. They set a “buy” rating and a $11.00 price target on the stock. HC Wainwright started coverage on shares of Heat Biologics in a report on Tuesday, June 26th. They set a “buy” rating and a $6.00 price target on the stock. Finally, ValuEngine upgraded shares of Heat Biologics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $13.17.
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Recommended Story: Diversification For Individual Investors
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.